Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progressing prostate carcinoma.

M J Haut1, J F Harryhill, J Rosenstock

  • 1Pennsylvania Hospital, Karnell Cancer Center, 230 West Washington Square, Philadelphia, PA 19106, USA. mjhaut@juno.com

The Oncologist
|April 18, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Finishing and Polishing Procedures and Glaze Application on Physical Properties of a Fine-Structure Feldspathic Ceramic.

The European journal of prosthodontics and restorative dentistry·2023
Same author

The Effect of Ethanol Associated with Universal Adhesive on Resin Composite Adhesion to Different Dentin Depths: A Long-Term In Vitro Study.

The European journal of prosthodontics and restorative dentistry·2023
Same author

Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300U/mL vs glargine 100U/mL in T2DM.

Diabetes & metabolism·2018
Same author

Influence of Different Ceramic Systems on Marginal Misfit.

The European journal of prosthodontics and restorative dentistry·2017
Same author

Efficacy and safety of linagliptin as add-on therapy to basal insulin and metformin in people with Type 2 diabetes.

Diabetic medicine : a journal of the British Diabetic Association·2015
Same author

Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial.

Diabetes, obesity & metabolism·2015
Same journal

Phase 2 Dose Expansion Trial of OBI-3424, a DNA-Alkylating Prodrug, in Patients with Advanced Solid Tumors Expressing AKR1C3.

The oncologist·2026
Same journal

Divergent Biology and Outcomes of Somatic Transformations in Germ Cell Tumors.

The oncologist·2026
Same journal

Modernizing Disease Assessment in Prostate Cancer Trials: The Prostate Cancer Working Group 4 Framework.

The oncologist·2026
Same journal

Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI trial.

The oncologist·2026
Same journal

Dose-Expansion Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors.

The oncologist·2026
Same journal

Comparison of Allo-HSCT outcomes after CAR-T therapy versus chemotherapy in pediatric patients with relapsed/refractory B-ALL: a retrospective study.

The oncologist·2026
See all related articles

This case study highlights advanced prostate cancer management. Early intervention with salvage radiation therapy for rising PSA levels improves outcomes, while chemotherapy offers palliation for hormone-resistant disease.

Area of Science:

  • Oncology
  • Urology
  • Radiation Oncology
  • Medical Oncology

Background:

  • Radical prostatectomy with pelvic lymphadenectomy can result in positive margins, leading to local recurrence and systemic disease progression.
  • Multidisciplinary therapeutic strategies are crucial for managing prostate cancer at various stages, from initial treatment to advanced disease.

Observation:

  • Prognostic tools incorporating prostate-specific antigen (PSA) level, Gleason score, and invasion parameters aid in selecting optimal initial therapy (monotherapy vs. adjuvant/neoadjuvant approaches).
  • Salvage radiation therapy for rising PSA levels (<1 ng/ml) in high-risk patients achieves up to 75% long-term PSA control, significantly better than delayed treatment.
  • Chemotherapy, including mitoxantrone and combination therapies (estramustine with taxanes or other agents), provides palliation and disease control for hormone-resistant metastatic prostate cancer.

Related Experiment Videos

Findings:

  • Early salvage radiation therapy in high-risk patients with minimal PSA rise yields superior long-term biochemical control compared to delayed intervention.
  • Chemotherapeutic regimens demonstrate efficacy in reducing tumor burden and PSA levels in patients with advanced, hormone-refractory prostate cancer.

Implications:

  • Optimizing treatment selection through prognostic tools and timely intervention, particularly with salvage radiation, can improve long-term outcomes for prostate cancer patients.
  • Advances in chemotherapy offer valuable therapeutic options for managing metastatic and hormone-resistant prostate cancer, improving palliation and disease control.